267 related articles for article (PubMed ID: 17503669)
1. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.
Cihlar T; Ray AS; Laflamme G; Vela JE; Tong L; Fuller MD; Roy A; Rhodes GR
Antivir Ther; 2007; 12(2):267-72. PubMed ID: 17503669
[TBL] [Abstract][Full Text] [Related]
2. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Tong L; Phan TK; Robinson KL; Babusis D; Strab R; Bhoopathy S; Hidalgo IJ; Rhodes GR; Ray AS
Antimicrob Agents Chemother; 2007 Oct; 51(10):3498-504. PubMed ID: 17664327
[TBL] [Abstract][Full Text] [Related]
3. Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3.
Uwai Y; Motohashi H; Tsuji Y; Ueo H; Katsura T; Inui K
Biochem Pharmacol; 2007 Jun; 74(1):161-8. PubMed ID: 17462604
[TBL] [Abstract][Full Text] [Related]
4. Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate.
Mizuno N; Takahashi T; Iwase Y; Kusuhara H; Niwa T; Sugiyama Y
Drug Metab Dispos; 2007 Aug; 35(8):1429-34. PubMed ID: 17502342
[TBL] [Abstract][Full Text] [Related]
5. Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
Cihlar T; Laflamme G; Fisher R; Carey AC; Vela JE; Mackman R; Ray AS
Antimicrob Agents Chemother; 2009 Jan; 53(1):150-6. PubMed ID: 19001108
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of active renal tubular efflux of tenofovir.
Ray AS; Cihlar T; Robinson KL; Tong L; Vela JE; Fuller MD; Wieman LM; Eisenberg EJ; Rhodes GR
Antimicrob Agents Chemother; 2006 Oct; 50(10):3297-304. PubMed ID: 17005808
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.
Stray KM; Bam RA; Birkus G; Hao J; Lepist EI; Yant SR; Ray AS; Cihlar T
Antimicrob Agents Chemother; 2013 Oct; 57(10):4982-9. PubMed ID: 23896476
[TBL] [Abstract][Full Text] [Related]
8. Transport of the natural sweetener stevioside and its aglycone steviol by human organic anion transporter (hOAT1; SLC22A6) and hOAT3 (SLC22A8).
Srimaroeng C; Chatsudthipong V; Aslamkhan AG; Pritchard JB
J Pharmacol Exp Ther; 2005 May; 313(2):621-8. PubMed ID: 15644426
[TBL] [Abstract][Full Text] [Related]
9. Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4.
El-Sheikh AA; Greupink R; Wortelboer HM; van den Heuvel JJ; Schreurs M; Koenderink JB; Masereeuw R; Russel FG
Transl Res; 2013 Dec; 162(6):398-409. PubMed ID: 24036158
[TBL] [Abstract][Full Text] [Related]
10. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).
Uwai Y; Ida H; Tsuji Y; Katsura T; Inui K
Pharm Res; 2007 Apr; 24(4):811-5. PubMed ID: 17372702
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
Borroto-Esoda K; Vela JE; Myrick F; Ray AS; Miller MD
Antivir Ther; 2006; 11(3):377-84. PubMed ID: 16759055
[TBL] [Abstract][Full Text] [Related]
12. Renal organic anion transporters OAT1 and OAT3 mediate the cellular accumulation of 5-sulfooxymethylfurfural, a reactive, nephrotoxic metabolite of the Maillard product 5-hydroxymethylfurfural.
Bakhiya N; Monien B; Frank H; Seidel A; Glatt H
Biochem Pharmacol; 2009 Aug; 78(4):414-9. PubMed ID: 19394312
[TBL] [Abstract][Full Text] [Related]
13. Uptake of chemically reactive, DNA-damaging sulfuric acid esters into renal cells by human organic anion transporters.
Bakhiya N; Stephani M; Bahn A; Ugele B; Seidel A; Burckhardt G; Glatt H
J Am Soc Nephrol; 2006 May; 17(5):1414-21. PubMed ID: 16597690
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters.
Kohler JJ; Hosseini SH; Green E; Abuin A; Ludaway T; Russ R; Santoianni R; Lewis W
Lab Invest; 2011 Jun; 91(6):852-8. PubMed ID: 21403643
[TBL] [Abstract][Full Text] [Related]
15. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Kiser JJ; Carten ML; Aquilante CL; Anderson PL; Wolfe P; King TM; Delahunty T; Bushman LR; Fletcher CV
Clin Pharmacol Ther; 2008 Feb; 83(2):265-72. PubMed ID: 17597712
[TBL] [Abstract][Full Text] [Related]
16. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A).
Motohashi H; Uwai Y; Hiramoto K; Okuda M; Inui K
Eur J Pharmacol; 2004 Oct; 503(1-3):25-30. PubMed ID: 15496291
[TBL] [Abstract][Full Text] [Related]
17. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.
Chu XY; Bleasby K; Yabut J; Cai X; Chan GH; Hafey MJ; Xu S; Bergman AJ; Braun MP; Dean DC; Evers R
J Pharmacol Exp Ther; 2007 May; 321(2):673-83. PubMed ID: 17314201
[TBL] [Abstract][Full Text] [Related]
18. Interaction characteristics of flavonoids with human organic anion transporter 1 (hOAT1) and 3 (hOAT3).
Hong SS; Seo K; Lim SC; Han HK
Pharmacol Res; 2007 Dec; 56(6):468-73. PubMed ID: 17920288
[TBL] [Abstract][Full Text] [Related]
19. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Gérard L; Chazallon C; Taburet AM; Girard PM; Aboulker JP; Piketty C
Antivir Ther; 2007; 12(1):31-9. PubMed ID: 17503745
[TBL] [Abstract][Full Text] [Related]
20. Characterization of methotrexate transport and its drug interactions with human organic anion transporters.
Takeda M; Khamdang S; Narikawa S; Kimura H; Hosoyamada M; Cha SH; Sekine T; Endou H
J Pharmacol Exp Ther; 2002 Aug; 302(2):666-71. PubMed ID: 12130730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
